Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27979731 | 0.83 | MEN1 (0.48) | MEN1KMT2ABCHEACHENPY5R | |
| SCHEMBL27979879 | 0.79 | MEN1 (0.45) | MEN1KMT2ABCHEACHENPY5R | |
| SCHEMBL27979704 | 0.79 | MEN1 (0.48) | MEN1KMT2ABCHEACHENPY5R | |
| SCHEMBL29780042 | 0.78 | BCHE (0.59) | MEN1KMT2ABCHEACHENPY5R | |
| SCHEMBL150044 | 0.78 | BCHE (0.59) | MEN1KMT2ABCHEACHENPY5R | |
| SCHEMBL3337353 | 0.78 | GPR3 (0.57) | MEN1KMT2ABCHEACHEMAPT | |
| SCHEMBL5096226 | 0.78 | NPY5R (0.47) | MEN1KMT2ABCHEACHENPY5R | |
| SCHEMBL15458634 | 0.76 | MEN1 (0.58) | MEN1KMT2ABCHEACHENPY5R | |
| SCHEMBL22336451 | 0.76 | KMT2A (0.54) | MEN1KMT2ABCHEACHENPY5R | |
| SCHEMBL5092382 | 0.75 | CNR2 (0.64) | MAPTTSHRATMHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125812-B2 | USE OF ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX LTD (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | disclosed |
| EP-2125812-B1 | USE OF ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX LTD (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | disclosed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, SNCA, CHAT | MEN1 4437/4885KMT2A 588/4885BCHE 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.